Peer-reviewed papers

In these examples of medical writing work, my name is listed in the Acknowledgments as providing writing or editorial support.

  1. Knorr B, Matz J, Bernstein JA, Nguyen H, Seidenberg BC, Reiss TF, Becker A. Montelukast for chronic asthma in 6- to 14-year-old children: a randomized, double-blind trial. Pediatric Montelukast Study Group. JAMA 1998;279:1181-1186. PubMed Link
  2. Pols HA, Felsenberg D, Hanley DA, Stepan J, Munoz-Torres M, Wilkin TJ, Qin-sheng G, Galich AM, Vandormael K, Yates AJ, Stych B. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group. Osteoporos Int 1999;9:461-468. PubMed Link
  3. Knorr B, Franchi LM, Bisgaard H, Vermeulen JH, LeSouef P, Santanello N, Michele TM, Reiss TF, Nguyen HH, Bratton DL. Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years. Pediatrics 2001;108:E48. PubMed Link
  4. Knorr B, Nguyen HH, Kearns GL, Villaran C, Boza ML, Reiss TF, Rogers JD, Zhang J, Larson P, Spielberg S. Montelukast dose selection in children ages 2 to 5 years: comparison of population pharmacokinetics between children and adults. J Clin Pharmacol 2001;41:612-619. PubMed Link
  5. Storms W, Michele TM, Knorr B, Noonan G, Shapiro G, Zhang J, Shingo S, Reiss TF. Clinical safety and tolerability of montelukast, a leukotriene receptor antagonist, in controlled clinical trials in patients aged > or = 6 years. Clin Exp Allergy 2001;31:77-87. PubMed Link
  6. Lainez MJ, Lopez A, Pascual AM. Effects on productivity and quality of life of rizatriptan for acute migraine: a workplace study. Headache 2005;45:883-890. PubMed Link 
  7. Lainez MJ, Evers S, Kinge E, Allais G, Allen C, Rao NA, Massaad R, Lis K. Preference for rizatriptan 10-mg wafer vs. eletriptan 40-mg tablet for acute treatment of migraine. Cephalalgia 2006;26:246-256. PubMed Link
  8. Price D, Holgate ST. Improving outcomes for asthma patients with allergic rhinitis: conclusions from the MetaForum conferences. BMC Pulm Med 2006;6 Suppl 1:S7. PubMed Link 
  9. Jeffery PK, Haahtela T. Allergic rhinitis and asthma: inflammation in a one-airway condition. BMC Pulm Med 2006;6 Suppl 1:S5. PubMed Link
  10. Price D, Thomas M. Breaking new ground: challenging existing asthma guidelines. BMC Pulm Med 2006;6 Suppl 1:S6. PubMed Link
  11. Bolognese L. The emerging role of platelet glycoprotein IIb/IIIa inhibitors in managing high-risk patients with non-ST segment elevation acute coronary syndromes. Curr Med Res Opin 2007;23:1217-1226. PubMed Link
  12. van ‘t Hof AWJ, Hamm C, Rasoul S, Guptha S, Paolini JF, ten Berg JM, on behalf of the On-TIME 2 investigators. Ongoing tirofiban in myocardial infarction evaluation (On-TIME) 2 trial: rationale and study design. EuroIntervention 2007;3:371-380. PubMed Link
  13. Ballatori E, Roila F, Ruggeri B, Betti M, Sarti S, Soru G, Cruciani G, Di Maio M, Andrea B, Deuson RR. The impact of chemotherapy-induced nausea and vomiting on health-related quality of life. Support Care Cancer 2007;15:179-185. PubMed Link
  14. Garcia ML, Baos V, Lainez M, Pascual J, Lopez-Gil A. Responsiveness of migraine-ACT and MIDAS questionnaires for assessing migraine therapy. Headache 2008;48:1349-1355. PubMed Link
  15. Price D, Berg J, Lindgren P. An economic evaluation of NIOX MINO airway inflammation monitor in the United Kingdom. Allergy 2009;64:431-438. PubMed Link 
  16. Thomas M, Price D, Chrystyn H, Lloyd A, Williams AE, von Ziegenweidt J. Inhaled corticosteroids for asthma: impact of practice level device switching on asthma control. BMC Pulm Med 2009 Jan 2;9(1):1. PubMed Link
  17. Haughney J, Price D, Barnes NC, Virchow JC, Roche N, Chrystyn H. Choosing inhaler devices for people with asthma: current knowledge and outstanding research needs. Respir Med 2010;104:1237-1245. PubMed Link
  18. Papi A, Haughney J, Virchow JC, Roche N, Palkonen S, Price D. Inhaler devices for asthma: a call for action in a neglected field. Eur Respir J 2011;37:982-985. PubMed Link
  19. Price D, Musgrave S, Wilson E, Sims E, Shepstone L, Blyth A, Murdoch J, Mugford M, Juniper E, Ayres J, Wolfe S, Freeman D, Lipp A, Gilbert R, Harvey I. A pragmatic single-blind randomised controlled trial and economic evaluation of the use of leukotriene receptor antagonists in primary care at steps 2 and 3 of the national asthma guidelines (ELEVATE study). Health Technol Assess 2011;15:1-132. PubMed Link
  20. Aapro M, Molassiotis A, Dicato M, Pelaez I, Rodriguez-Lescure A, Pastorelli D, Ma L, Burke T, Gu A, Gascon P, Roila F. The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER). Ann Oncol 2012;23:1986-1992. PubMed Link
  21. Humphreys S, Pellissier J, Jones A. Cost-effectiveness of an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer in the UK. Cancer Manag Res 2013;5:215-224. PubMed Link
  22. Wilk A, Sajjan S, Modi A, Fan CP, Mavros P. Post-fracture pharmacotherapy for women with osteoporotic fracture: analysis of a managed care population in the USA. Osteoporos Int 2014;25:2777-2786. PubMed Link
  23. Conaghan PG, Peloso PM, Everett SV, Rajagopalan S, Black CM, Mavros P, Arden NK, Phillips CJ, Rannou F, van de Laar MA, Moore RA, Taylor SD. Inadequate pain relief and large functional loss among patients with knee osteoarthritis: evidence from a prospective multinational longitudinal study of osteoarthritis real-world therapies. Rheumatology (Oxford) Epub ahead of print. PubMed Link
  24. Keefe DM, Chan A, Kim HK, Hsieh RK, Yu S, Wang Y, Nicholls RJ, Burke TA. Rationale and design of the Pan Australasian chemotherapy-induced emesis burden of illness study. Support Care Cancer 2015;23:253-261. PubMed Link
  25. Yu S, Burke TA, Chan A, Kim HK, Hsieh RK, Hu X, Liang JT, Banos A, Spiteri C, Keefe DM. Antiemetic therapy in Asia Pacific countries for patients receiving moderately and highly emetogenic chemotherapy-a descriptive analysis of practice patterns, antiemetic quality of care, and use of antiemetic guidelines. Support Care Cancer 2015;23:273-282. PubMed Link
  26. Kerkhof M, Freeman D, Jones R, Chisholm A, Price DB. Predicting frequent COPD exacerbations using primary care data. Int J Chron Obstruct Pulmon Dis 2015;10:2439-2450. PubMed Link
  27. Chrystyn H, Price DB, Molimard M, Haughney J, Bosnic-Anticevich S, Lavorini F, Efthimiou J, Shan D, Sims E, Burden A, Hutton C, Roche N. Comparison of serious inhaler technique errors made by device-naive patients using three different dry powder inhalers: a randomised, crossover, open-label study. BMC Pulm Med 2016;16:12. PubMed Link
  28. Westerik JA, Carter V, Chrystyn H, et al. Characteristics of patients making serious inhaler errors with a dry powder inhaler and association with asthma-related events in a primary care setting. J Asthma 2016:1-9. PubMed Link
  29. McKay C, Burke T, Cao X, Abernethy AP, Carbone DP. Treatment patterns for advanced non-small-cell lung cancer after platinum-containing therapy in U.S. community oncology clinical practice. Clin Lung Cancer 2016;17:449-460 e447. PubMed Link
  30. Lee DH, Isobe H, Wirtz H, Aleixo SB, Parente P, de Marinis F, Huang M, Arunachalam A, Kothari S, Cao X, Donnini N, Woodgate AM, de Castro J. Health care resource use among patients with advanced non-small cell lung cancer: the PIvOTAL retrospective observational study. BMC Health Serv Res. 2018;18:147. PubMed Link
  31. Cowey CL, Liu FX, Black-Shinn J, Stevinson K, Boyd M, Frytak JR, Ebbinghaus SW. Pembrolizumab utilization and outcomes for advanced melanoma in US community oncology practices. J Immunother. 2018;41:86-95. PubMed Link
  32. Wang Y, Cho SH, Lin HC, Ghoshal AG, Bin Abdul Muttalif AR, Thanaviratananich S, Tunceli K, Urdaneta E, Zhang D, Faruqi R. Practice patterns for chronic respiratory diseases in the Asia-Pacific region: a cross-sectional observational study. Int Arch Allergy Immunol. 2018:1-11. PubMed Link